Loading...

TVRD TVARDI THERAPEUTICS INC US FDA Inspections 8-K Filing

TVRD

TVRD

TVARDI THERAPEUTICS INC

(TVRD)

2025 8-K

Financial Results Update

Annual Meeting Notice

Corporate Update

Executive Compensation Changes

Corporate Presentation Update

Financial Results Report

Trial Update Issued

Financial Results

Investor Meetings

Clinical Trials

Merger of Equals

Merger Completion

Merger Announcement

Stockholder Meeting

Compliance Update

Stock Split Announcement

Filing Amendment

Merger Agreement

Nasdaq Compliance Notice

Discontinuation of Clinical...

Discontinuation of Clinical...

Amendment of Certificate of...

Financial Results Announcement

Departure of Director

Financial Results Announcement

Strategic Reprioritization ...

Discontinuation of Clinical...

Regulation FD Disclosure

Financial Results Announcement

Agreement with HCRx and Hea...

Earnings Reports

Appointment of Director

Annual Meeting of Stockholders

Regulation FD Disclosure

Financial Results Announcement

Regulation FD Disclosure

Regulation FD Disclosure

Earnings Report

Regulation FD Disclosure

External Links:

On May 27, 2025, Tvardi Therapeutics announced the completion of patient enrollment in a Phase 2 clinical trial for TTI-101, aimed at treating Idiopathic Pulmonary Fibrosis.

AI Assistant

TVARDI THERAPEUTICS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.